Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home›Services›Medical & scientific writing

Medical and Regulatory Writing Services

Medical Writing Services

Pubrica provides medical writing services for researchers, pharmaceutical and biotechnology companies, medical device and diagnostics manufacturers, digital health teams and contract research organisations. Our subject-specialist medical writers prepare academic and clinical manuscripts, regulatory documents such as protocols, clinical study reports and clinical evaluation reports, pharmaceutical and biotech content, medical device and digital health documentation, and patient and healthcare professional communication. We also provide medical editing for documents you have written. Each document is written to the standard that governs it and in the register its reader expects.

Example project summary · a device submission EU MDR · Class IIa

Every claim traced to the clinical evidence behind itAppraised

Intended purpose identical across CER, IFU and labelling3 of 3

Residual risks carried into the risk file and the IFUNamed

Every gap answered by a PMCF objective with a threshold4 of 4

Referenced, checked for originality and version-controlledReports issued

Data → scope → evidence → draft → QC → submission

Service Scope

Six Medical Writing Service Areas, Available Individually

Our medical writing services cover the product and research lifecycle, from early-stage research through regulatory submission to patient communication. Each service area can be commissioned on its own.

Scientific and academic medical writing Manuscripts written from your data or developed from a draft, literature and systematic reviews, meta-analyses, case reports, thesis and dissertation chapters, and continuing medical education material. Each is written to the reporting guideline the study type requires and formatted to the journal, with authorship and disclosure agreed at the outset.
Regulatory medical writing Clinical trial protocols and their amendments, investigator brochures, informed consent documents, clinical study reports to ICH E3, common technical document summaries and the clinical overview in Module 2.5, patient narratives, periodic safety update reports and risk management plans. Each is written for the assessor who will review it, against the guidance current for your submission.
Medical device and digital health documentation Clinical evaluation reports under MDR Annex XIV with the literature appraised and matrixed, clinical investigation reports to ISO 14155, post-market surveillance and PMCF plans and reports, instructions for use to ISO 20417, labelling and package inserts, and for software as a medical device the performance report, the validation summary and the SaMD compliance narrative.
Pharmaceutical and biotech content Scientific white papers, product monographs and dossiers, target product profiles, mechanism-of-action narratives, medical science liaison (MSL) decks built for reactive use, competitive landscape summaries, health economics and outcomes research (HEOR) support, and the scientific content behind an investor deck. The scientific content remains accurate within the commercial context.
Patient and healthcare professional communication Plain-language trial summaries, patient information leaflets and education materials written for a defined reading age, healthcare professional (HCP) brochures and newsletters, frequently asked questions, and website and digital content. Unfavourable findings are reported with the same prominence as favourable ones.
Medical editing and quality support Medical editing of a document you have written, at substantive or language level, addressing the argument as well as the prose. We also provide reference checking against the source, reference management and style conversion, consistency checking across a document set, originality checking, and formatting to a journal, template or submission structure.

Optional additions

Visual and graphical abstracts based on the study findings, scripts and storyboards for scientific animation, and data presentation for algorithm validation, so that a performance claim is clear to a reviewer who is not a data scientist. These are quoted alongside a writing project rather than as standalone services.

Deliverables

Fifteen Types of Medical and Regulatory Documents

Documents for academic publication, regulatory submission, device conformity and commercial communication, each with its own structure, reader and common reasons for rejection.

Journal manuscriptWritten from your data or developed from a draft, to CONSORT, PRISMA, STROBE, STARD or CARE as the study type requires, and formatted to the journal. Prepared for a methods reviewer who checks each reporting item.
Clinical trial protocolWritten to SPIRIT with the estimand stated, the analysis pre-specified and the operational detail an ethics committee asks about answered in the document rather than in a covering email.
Investigator brochureThe preclinical and clinical evidence assembled for the investigators running the study, updated as the evidence changes, with a risks section written for quick reference during the study.
Informed consent documentsConsent forms and participant information sheets written to satisfy an ethics committee while remaining readable for the participant who signs them.
Clinical study reportWritten to ICH E3: exhaustive, neutral and cross-referenced to the listings and narratives that support each statement, so that it withstands an assessor’s comparison against the protocol and the statistical analysis plan.
CTD summaries and Module 2.5The clinical summary and the clinical overview, in which the benefit-risk case is argued rather than restated. The clinical overview is the document in a dossier that takes a position, and the one an assessor reads first.
Safety and pharmacovigilance documentsPatient narratives, periodic safety update reports, development safety update reports and risk management plans, written to the format the authority expects and on the cycle it sets.
Clinical evaluation reportUnder MDR Annex XIV Part A with MEDDEV 2.7/1 rev 4: the state of the art established and quantified, every source appraised, and each residual risk carried explicitly into the risk file and the labelling.
Clinical investigation reportWritten to ISO 14155 and reported against the acceptance criteria in the investigation plan, including endpoints that were not met, in the results section.
Instructions for use and labellingWritten to ISO 20417 and MDR Annex I, with intended purpose, limitations and warnings stated as instructions, concise enough to read during a clinical shift and suitable for translation into every required language.
PMS and PMCF documentsSurveillance plans, post-market clinical follow-up plans and their periodic reports, with each objective traced to a gap identified in the clinical evaluation and given a method and a threshold.
SaMD and AI documentationAlgorithm performance reports, validation summaries, software instructions for use and the compliance narrative, declaring training and test separation, the reference standard and any dataset enrichment, as reviewers expect.
Plain-language summariesTrial results for participants and the public under the EU Clinical Trials Regulation, written using natural frequencies at an appropriate reading age, with unfavourable findings included.
Field medical and scientific decksSlides built for reactive use, with efficacy and safety data on the same slide, references on the page, and version control that stands up in a medical affairs audit.
Commercial and scientific communicationWhite papers, product monographs, healthcare professional and patient-facing material, and website copy, with claims kept within what the approved labelling or intended purpose supports, as regulation requires.

Therapeutic Areas We Cover

Writers are assigned by therapeutic area rather than by availability, across oncology, cardiology, neurology and psychiatry, endocrinology, haematology, gastroenterology, dermatology, urology, immunology and rheumatology, infectious disease and vaccines, respiratory and critical care, obstetrics and gynaecology, paediatrics and neonatology, geriatrics, rare and genetic disease, ophthalmology, nephrology, anaesthesia and pain, surgery, nutrition, public health and epidemiology, and medical devices from Class I to Class III alongside in vitro diagnostics and digital health. Where a project spans two areas, such as a device with a behavioural endpoint or an algorithm making an oncology claim, the team includes specialists in both, so that the document is credible to reviewers from each field.

Device and IVD conformity

Clinical Evaluation Scoping for Medical Devices

Notified bodies often return clinical evaluation reports because of scoping problems rather than writing quality: a clinical investigation considered exempt on one reading and required on another, an equivalence route without supporting evidence, or a PMCF plan without a defined threshold. The tool below scopes the clinical evaluation from the device: whether a clinical investigation is required and under which exemption, what the CER, the PMCF plan and the SSCP must contain, how often the regulation requires updates, and the legal basis for each answer.

01

Answer six questions about the device and see what the clinical evaluation owes: whether a clinical investigation is required, which documents the scope produces, how often each has to be updated, and which article says so.

MDR 2017/745 · IVDR 2017/746 · read September 2026
Which regulation
Class IIa · MDR 2017/745scoped from the regulation’s articles

Not mandated

Clinical investigation

Not required

Summary of safety and clinical performance

Every 2 years

Periodic safety update report

Obligationwhat applies
Clinical evaluationRequired — Article 61(1), Annex XIV Part A
Clinical investigationNot mandated
SSCP — Article 32Not required
PSUR — Article 86Updated when necessary and at least every two years
PMCF — Annex XIV Part BPlan with a justified time schedule, and a PMCF evaluation report
Transition deadline — Regulation (EU) 2023/60731 December 2028
Why the clinical investigation answer is what it is

Article 61 requires a clinical evaluation for every device, whatever its class, but a clinical investigation is only mandated for implantable and class III devices. Whether you need one here is decided by whether the data you already have closes the gaps your clinical evaluation plan identifies.

How often it has to be updated

The Regulation sets no numeric interval for a device in this class. Article 61(11) requires the clinical evaluation to be updated throughout the life cycle, and Annex XIV Part B requires a justified time schedule for PMCF. The familiar two-to-five-year figure comes from MEDDEV 2.7/1 rev 4 section 6.2.3, which recommends at least annually where the device carries significant risks or is not yet well established, and every two to five years where it does not and is. That document is MDD-era guidance, not MDR law — useful for setting a defensible schedule, not a rule you can cite as a requirement.

The documents this scope produces6

Clinical evaluation plan — Annex XIV Part A(1)(a): the safety and performance requirements needing clinical support, the intended purpose, target groups with indications and contraindications, intended clinical benefits with measurable outcomes, the methods for assessing safety and performance, the parameters for benefit-risk acceptability, and a clinical development plan with milestones.

Literature search protocol and report — The systematic identification of available clinical data and, explicitly, of the gaps it leaves. Written as a protocol before the search, so that the search is reproducible and the appraisal criteria were set in advance rather than after the results were seen.

Clinical evaluation report — Annex XIV Part A(4): the analysis and the conclusions on safety, performance and benefit-risk. Favourable and unfavourable data both go into the technical documentation — leaving the unfavourable out is one of the more common non-conformities.

Equivalence justification — Annex XIV Section 3: technical, biological and clinical characteristics compared, with no clinically significant difference in safety or performance, and demonstrated access to the data you are relying on.

PMCF plan — Annex XIV Part B(6): general and specific methods, a rationale for why they are appropriate, cross-references to the CER and the risk management file, the standards and guidance applied, and a detailed, justified time schedule.

PMCF evaluation report — Annex XIV Part B(7)–(8): the findings analysed, fed back into the clinical evaluation and the risk management file, with corrective measures where indicated.

What else decides it

The extended transition under Regulation (EU) 2023/607 runs to 31 December 2027 for class III and class IIb implantable devices, and to 31 December 2028 for other class IIb, class IIa and class I devices requiring notified body involvement. It is conditional: the device must still comply with the Directive, must not have changed significantly in design or intended purpose, must present no unacceptable risk, and the manufacturer must have had an MDR-compliant quality system and a lodged application by 26 May 2024 and a signed agreement with the notified body by 26 September 2024. If any of those is missing, the extension does not apply.

The Commission published a substantial MDR and IVDR reform package in December 2025, which would among other things relax the third-party equivalence contract requirement. It is a proposal: it has not been adopted, and nothing in it changes what is required today.

Sources and date. Regulation (EU) 2017/745 Articles 32, 61, 85 and 86 and Annex XIV; Regulation (EU) 2017/746 Articles 29 and 56 and Annex XIII; Regulation (EU) 2023/607 and 2024/1860 for the transition periods; MDCG 2020-6 on sufficient clinical evidence for legacy devices and MDCG 2020-3 on significant change; MEDDEV 2.7/1 rev 4 where it is named as guidance rather than law. Read in September 2026. This scopes the work — it is not regulatory advice, it cannot see your technical documentation, and your notified body’s reading of a borderline case is the one that counts.

Scope and Limitations of the Tool

This is a scoping tool, and it cites the article behind each answer so that you can check it. It is not regulatory advice, it cannot see your technical documentation, and in borderline cases your notified body’s interpretation applies. It does not estimate page counts or timelines, because no authoritative source exists for either, and it does not anticipate the reform package the Commission published in December 2025, which is a proposal and changes nothing today. It is one of a set of open calculators and checkers on our free research tools page, all of which run in your browser and ask for nothing.

Who we serve

Clients We Support with Medical Writing

Five kinds of client across the product and research lifecycle, each needing content that is accurate, compliant and written for the audience that will act on it.

Researchers and academicsManuscripts, reviews, case reports and thesis chapters, written to the reporting guideline the study type requires and formatted to the journal, with authorship and disclosure agreed at the start.
Pharmaceutical and biotechnology companiesProtocols, investigator brochures, clinical study reports, CTD summaries and safety documents, alongside the white papers, monographs and scientific decks a programme needs on the commercial side.
Medical device and diagnostics manufacturersClinical evaluation reports, investigation reports, instructions for use, labelling and surveillance plans, written as a consistent set, which is what a notified body checks.
Digital health and clinical AI teamsPerformance reports, validation summaries, SaMD compliance narratives and software instructions for use, written so that an algorithm’s claims are clear to a clinical reviewer who is not a data scientist.
Clinical and contract research organisationsOverflow and specialist writing within a programme you are already running, using your templates, style guide and quality system.

Readers We Write For

Each document is written for a specific reader. A regulatory assessor checks whether the study was run and reported as planned, and expects cross-references rather than conclusions. A notified body reviewer checks whether the clinical evidence supports the intended purpose and compares documents against each other. A peer reviewer assesses whether the finding is credible and new. A prescriber reading product information in a clinic needs a frequency category and an instruction. A clinician using a device needs limitations written as clear instructions. A trial participant needs natural frequencies, short sentences and unfavourable results reported in full. Our writers adapt the register to each reader while keeping the results consistent.

Compliance and Standards

Medical Writing Regulatory and Reporting Standards

Pubrica works in compliance with this guidance. The governing standard for each document is confirmed before drafting, because it determines the document’s structure.

ICHE3 · E6(R3) · E9

ICH and Good Clinical Practice (ICH-GCP)

E3 gives a clinical study report its structure and decides what has to appear in which section; E6(R3) governs how the study it reports was conducted, and moves towards a risk-proportionate approach; E9 governs the statistical principles and, through the addendum, the estimand the report has to state. Protocols, informed consent documents, investigator brochures and CSRs are all written against this set, and an assessor reads them against it too.

MDRIVDR · MDCG

EU device regulation (MDR, IVDR, MEDDEV, MDCG)

Clinical evaluation under Annex XIV Part A with MEDDEV 2.7/1 rev 4 for the appraisal method, post-market clinical follow-up under Annex XIV Part B, and the MDCG guidance that fills the gaps between them — MDCG 2020-7 for the PMCF plan among others. For in vitro diagnostics the performance evaluation route under the IVDR differs, and applying the device route to a diagnostic is a common and costly error.

ISO14155 · 20417

Device investigation and information supplied (ISO 14155, ISO 20417)

ISO 14155 for the conduct and reporting of a clinical investigation of a medical device — the device equivalent of GCP, with its own report structure. ISO 20417 for what information has to be supplied with the device and how: identification, intended purpose, residual risks, warnings and the conditions under which the device must not be used. Together they decide what the technical file can support and what the labelling may therefore say.

Reporting guidelines for publication (CONSORT, PRISMA, STROBE, STARD)

CONSORT for trials and SPIRIT for their protocols, PRISMA for systematic reviews, STROBE for observational studies, STARD for diagnostic accuracy, ARRIVE for animal work and CARE for case reports — with the AI extensions where an algorithm is the intervention. Journals increasingly require the completed checklist as a submitted item, and completing it honestly is what surfaces the missing methods detail before a reviewer does.

ICMJECOPE · WAME

Publication ethics and authorship (ICMJE, COPE, WAME)

The four ICMJE authorship criteria, the declarations that go with them, and COPE’s guidance on the disputes that arise when they are not applied. This is also where professional medical writing is explicitly permitted and explicitly required to be disclosed. A writer who contributed substantially is named in the acknowledgements with the funding source stated, which distinguishes disclosed professional writing from ghostwriting.

Regulatory Authorities We Write For

Submissions are written for the authority that will read them: the FDA in the United States, the EMA and the national competent authorities across the European Union, the MHRA in the United Kingdom, the TGA in Australia, the SFDA in Saudi Arabia, the PMDA in Japan and CDSCO in India, alongside the notified bodies that assess devices in Europe. The differences are substantial. A dossier assembled to the common technical document structure still has region-specific modules; a device approved in Europe under the MDR faces a different route with the FDA; and a document that satisfies one authority can require substantial rework for the next. Where a product is going to more than one region, the regional requirements are agreed before drafting begins.

Responsible Use of AI

Responsible Use of AI, with Traceable Human Authorship

Generative AI tools can draft a clinical section quickly, but an assessor must be able to trace every claim in a submission to its source document. A fluent sentence with no traceable source is less acceptable than a plain one that has it.

What we use it forFinding source material across a document set. Checking consistency of terms, figures and cross-references between documents. Drafting the first pass of highly templated sections where a writer then verifies every number against source.
What we do not use it forAnything that goes into a regulatory submission as drafted; clinical interpretation; safety narratives; benefit-risk reasoning; and any section where a claim cannot be traced back to a named source document.
What goes in your declarationThe tool, the stage it was used at, and the human oversight applied — because journals, funders and the ICMJE January 2026 update all now expect it, and an undeclared tool found later is treated as a research integrity matter rather than a style preference.

Why We Do Not Publish AI Accuracy Figures

Accuracy figures for AI tools are usually reported by the companies that sell them.

Pubrica does not quote a self-generated accuracy figure, because it would carry the same conflict of interest. Instead, we tell you which tool was used on your project, at which stage, and what a reviewer changed afterwards.

Methodology

How Our Medical Writing Process Works

A standardised process used for every document, from an academic manuscript to a regulatory submission, with the depth of each stage set by the document’s requirements.

Stage one

Consultation and scoping

A project associate and a subject-matter expert. We confirm the document’s purpose, its readers, the target authority or journal, the applicable regulatory or publication context, and the deadline. We also agree the full document set at this stage, because a single study often requires four documents, and planning them together keeps them consistent.

Stage two

Literature search and context gathering

Subject specialists and information specialists. We review the primary literature, grey literature, applicable guidance and your internal documents, such as protocols, product monographs, previous submissions and the risk file. For a clinical evaluation, the literature search is itself a regulated deliverable with a documented strategy and appraisal method.

Stage three

Structure agreed before drafting

The writer and you. An annotated outline showing every section, its content and its sources is signed off before drafting begins. Changes are quickest at outline stage; restructuring a 140-page clinical evaluation report later takes far longer and affects its cross-references.

Stage four

Medical writing and development

A writer qualified in your therapeutic area. The document is written in the appropriate register, with consistent terminology, every number traced to its source and every claim to its supporting evidence. Where a document belongs to a set, the intended purpose, claims and numbers are kept identical across all of them, because inconsistency between documents is what a reviewer finds first.

Stage five

Quality review and QC

An independent reviewer and the QC function. Checks cover scientific accuracy, compliance with the governing standard, verification of every reference against its source, numerical consistency across the document set, formatting to the journal or template, and originality. Each check is signed off separately, and no document is delivered with an open item.

Stage six

Delivery, revision and the audit trail

The project associate. The document is delivered with its QC and originality reports on request, version-controlled throughout, and revised within the agreed scope until it meets the agreed requirements. If a journal or authority returns questions, responding to them within the agreed scope is included.

Request a Free Document Requirements Assessment

Before quoting, a medical writer reviews your material and confirms which documents the work requires, which standard governs each one, and which must be consistent with each other. The assessment takes two business days and is free of charge. It can identify documents that are required but not yet planned, as well as documents that are not needed.

What to send us
The fieldClinical research, device, biotech, digital health
The regionUK, EU, US, GCC, India, Asia-Pacific
The readerA journal, a regulator, clinicians, patients
The materialData, protocol, draft, risk file, prior dossier
The rulesJournal, template or institutional guidelines
Any referencesSources you want used or cited

The two items most often omitted are the previous version of the document and any comments from a reviewer, assessor or notified body. Both show how the reader assessed the document, and revising without them risks receiving the same objection again.

Common Reasons for Rejection

Writing for the Correct Audience and Register

  1. A clinical study report that draws conclusionsThe assessor wanted a cross-reference to the listing that supports the statement. An argument where a citation belongs reads as advocacy and is queried.
  2. A CER claiming what the IFU does notA performance claimed in the clinical evaluation but absent from the instructions for use is among the most common major non-conformities a notified body raises.
  3. A plain-language summary that softensThe unwelcome number quietly dropped. Under the EU Clinical Trials Regulation that summary is a regulatory document, not communications copy.
  4. Efficacy on slide three, safety in the appendixThe finding in almost every medical affairs audit. The data on one slide or neither, with the reference on the page and version control that survives the audit.

Each of these documents is factually accurate but written in the wrong register. The result is an additional review cycle, a non-conformity or a compliance finding. For this reason we assign writers according to the register each document requires and confirm at the outset what it must not state.

Standard for every document
  • Written in its own register
  • Traced to its source
  • Referenced and checked
  • Consistent across the set
  • Under NDA
MD · PhDWriters with 5+ years in their therapeutic area
Since 2009Supporting researchers and industry worldwide
ICH · MDRGCP, FDA, EMA, MHRA, TGA, SFDA, ISO 14155
ISO 9001:2015Quality management certified · cert. H3CR9TCU20251212INDQM10N

Register and Audience

One Study Finding Across Different Document Types

Select a study, then follow it through the documents it must become. The figures stay the same, while the reader, the governing rules and what each document must or must not state all change, so each document is written in its own register.

Choose a study, then a document. The figures stay the same throughout. 7 documents · one set of numbers

The finding, stated once

Study 301. 1,319 adults with type 2 diabetes randomised to [drug] (n=658) or placebo (n=661) for 26 weeks. Mean HbA1c change from baseline −1.4% (SD 1.1) against −0.6% (SD 1.1); difference −0.80 percentage points (95% CI −0.92 to −0.68), p<0.001. ALT above three times the upper limit of normal in 27 of 658 (4.1%) against 12 of 661 (1.8%); two subjects met Hy’s law criteria on a single occasion and both resolved without intervention.

The documents it becomes

The same finding, written for this reader

Results section of the primary paper

Governed by CONSORT 2025 and the ICMJE recommendations, plus the journal’s own structured results format

Who reads itPeer reviewers, then readers in the field
What they decideWhether the finding is believable and adds to what is known
Length · sign-off3,000–4,000 words. The corresponding author, on behalf of all named authors.
Manuscript · ResultsCONSORT

Primary outcomeAt week 26, the mean reduction in HbA1c from baseline was 1.4 percentage points (SD 1.1) in the [drug] group and 0.6 percentage points (SD 1.1) in the placebo group. The between-group difference was −0.80 percentage points (95% CI −0.92 to −0.68; p<0.001) in the intention-to-treat population.

HarmsAlanine aminotransferase above three times the upper limit of normal was recorded in 27 of 658 participants (4.1%) assigned to [drug] and in 12 of 661 (1.8%) assigned to placebo. Two participants in the [drug] group met Hy’s law criteria on a single occasion; both had normalised by the following scheduled assessment without any change to study treatment.

What this register requires

Past tense, group-by-group denominators, and an effect estimate with its interval. Harms are reported in the results with the same care as efficacy, which CONSORT asks for explicitly and which manuscripts routinely compress into a sentence.

What it forbids

No interpretation here at all. Whether the benefit outweighs the hepatic signal belongs in the discussion, and a reviewer will say so. No frequency categories, no clinical instruction, and no claim about the drug beyond what this trial measured.

Written in the wrong register, this reads: [Drug] delivers a clinically meaningful 0.8% HbA1c reduction with a manageable safety profile. Every part of that sentence is a conclusion, two of them are promotional, and a methods reviewer will return the paper for it.

The extracts are written for this page and the figures in each scenario are internally consistent across every document in it. They are illustrative rather than real deliverables: the studies, the products and the numbers are invented, and no extract should be reused. Regulatory requirements also change — MEDDEV, MDCG and ICH guidance are revised, and the version that applies is the one current for your submission. We check that for your project rather than working from what applied last time.

Why Register Matters

Most returned documents are not factually wrong; they are written in the wrong register. Examples include a clinical study report that draws a conclusion where the assessor expected a cross-reference; a clinical evaluation report that claims a performance not carried in the instructions for use, which is among the most common major non-conformities a notified body raises; a plain-language summary that omits an unfavourable result; and a field medical deck with efficacy data on slide three and safety data in the appendix, which is the finding in almost every medical affairs audit. Each of these documents is accurate but unsuitable for its reader, and the result is an additional review cycle, a non-conformity or a compliance finding.

Our experts

Your Medical Writing Team

Your project is handled by a named team rather than an allocated pool. The same team stays with the project from scoping to delivery, the handover records which member completed each stage, and your project coordinator introduces each member before work begins.

Subject matter expertClinical or scientific expert matched to your topic

Reviews the scientific content for accuracy and confirms that each conclusion is supported by the evidence. Matched to your field rather than allocated from a rota.

Responsible forScientific accuracy and interpretation
Standards appliedICMJE, COPE and the applicable reporting guideline
FieldMatched to your topic
Medical writerDrafts the document to the applicable guideline

Writes the manuscript or document against the applicable reporting guideline and the target journal or funder requirements, with every statement traceable to its source.

Responsible forDrafting and source traceability
Standards appliedICMJE and the applicable reporting guideline
OutputSubmission-ready draft
BiostatisticianStatistical input where the work reports analysed data

Checks that statistical methods, tables and conclusions are consistent with the analysis plan and that the analysis can be reproduced.

Responsible forStatistical accuracy
Standards appliedICH E9 and the statistical analysis plan
ToolsR, SAS, Stata, Python
Second reviewerIndependent quality check before delivery

Checks the finished work independently against the agreed scope and the applicable checklist. Findings are logged and resolved before delivery.

Responsible forIndependent quality control
Standards appliedThe agreed scope and checklist
Signed off byProject lead

Sample work

Sample Quality Control Report

Every Pubrica document can be delivered with its quality control report. This example covers four documents from one device submission, checked against each other rather than individually. Use the tabs to view each part.

Document set QC report

Class IIa device · EU MDR · four documents checked against each other

Claim tracing · numerical consistency across the set · reference verification · findings by severity

1Four documents, read as one submissionClinical evaluation report, instructions for use, labelling text and the post-market clinical follow-up plan. Checked against each other rather than one at a time, because inconsistency between documents is what a notified body finds first and what no single-document review can catch.
2Claim tracingEvery performance and safety claim in any of the four traced back to the clinical evidence, and forward to every other document that repeats it. 34 claims traced; 31 consistent across the set.
3Numerical consistencyEvery figure compared across documents, including its rounding. A specificity reported as 88.7% in one document and 89% in another is a claim discrepancy rather than a typographical one, and it is read as one.
4Reference verification against the sourceEach cited work opened and checked for what it actually says, not matched against the citation. This is the slow part and the part most often skipped.
5Done by a reviewer who did not write itThe reviewer is independent of the writing team. A writer checking their own document set reliably re-reads what they meant rather than what is on the page.

4 documents · 34 claims · 84 referencesIndependent reviewer

Redacted extract · client and device details changedPage 1 of 4

The report is the check and the evidence that it happened. Use the tabs to see each part.

The critical finding is the reason the set is checked together. The clinical evaluation and the instructions for use each read correctly on their own. Side by side they make incompatible claims about the same device, and that is a major non-conformity rather than a wording problem — which is why it went to the client as a decision rather than being quietly resolved by an editor.

Six references in eighty-four were not as cited, including one retracted after the document was first drafted. We report that number rather than rounding it away, because a reference list nobody opened is the most common quiet defect in a regulatory document.

Documents checked against each otherNot one at a time, which is how the critical finding surfaced.
Every claim traced to its evidenceAnd forward to every document that repeats it.
References opened, not matchedSix discrepancies in eighty-four, each one reported.
Regulatory decisions escalated, not absorbedAn editor does not get to choose what a device claims.

On request, we will send a sample report based on a document set similar to yours, for the same regulation, device class or journal.

Medical writing · sample QC report

Document set QC report

Class IIa medical device · EU MDR · four documents checked against each other · claim tracing, numerical consistency, reference verification and findings by severity. Client, device and project details have been removed or changed. Ask us and we will send one built around a document set like yours.

1What was checked, and how

Four documents from one submission, read as a single set rather than one at a time. Most of what a notified body finds is not an error inside a document; it is a disagreement between two of them, and no single-document review can see it.

ElementHow it was handled
DocumentsClinical evaluation report, instructions for use, labelling text, and the post-market clinical follow-up plan.
ReviewerIndependent of the writing team. A writer checking their own document set re-reads what they meant rather than what is on the page.
Claim tracingEvery performance and safety claim traced back to the clinical evidence and forward to every other document repeating it. 34 claims traced.
Numerical consistencyEvery figure compared across documents, including its rounding. A value given as 88.7% in one document and 89% in another is a claim discrepancy, not a typographical one.
ReferencesEach cited work opened and read against the statement it supports, rather than matched against the citation. 84 references.
Search currencyThe literature search re-run to the delivery date, and anything new appraised.

What this is not: a regulatory review. We check that the documents say the same thing, that each claim has evidence behind it, and that each is written to the standard that governs it. Whether the regulatory strategy is right belongs to your qualified person.

2Findings

SeverityFindingWhat was done
CriticalThe clinical evaluation report (8.2) states performance across all three acquisition systems. The instructions for use (4.3) exclude system C. One of the two is wrong.Escalated the same day. Which one is correct is a regulatory decision about the intended purpose, not an editorial one, so it was not resolved in the document. A notified body comparing the two raises a major non-conformity.
MajorSpecificity appears as 88.7% in the clinical evaluation, 89% in the labelling text, and “approximately 90%” in the clinical summary.Escalated. All three describe one result; read together they describe three, and the third states a performance the evidence does not support.
MajorPMCF objective 3 commits to monitoring real-world performance, with no method, no sample and no decision threshold.Escalated with a drafted replacement. Nothing can satisfy or fail the objective as written, and this is the most common reason a PMCF plan is returned.
MinorNine items: one superseded MEDDEV revision cited, two cross-references left pointing at the wrong section after a renumber, inconsistent device nomenclature in the labelling, and five terminology drifts between documents.Corrected in place, listed individually in the findings log, and visible in the tracked copies.

What was already right, and is reported because it is. The intended purpose is stated identically in all four documents. Every residual risk identified in the clinical evaluation appears in the instructions for use. Every PMCF objective except the third traces to a gap the clinical evaluation named. A quality control report that lists only faults is not a review of the document; it is a list.

3Reference verification

Every reference opened and read against the statement it supports. This is the slow part of a quality check and the part most often skipped, and it is where a document quietly stops being defensible.

ResultCount
References checked84
Verified as cited78
Correct source, wrong page or section2
Review cited in place of the primary study3
Retracted since the document was first drafted1
Not traceable to any source0
  • The two locator errors were corrected. The claim is in the source; the pointer was not.
  • The three reviews were replaced with the primary studies they were themselves citing. A review is evidence of what a field believes, not of what a study found, and an assessor reading a clinical evaluation knows the difference.
  • The retracted paper was removed and the claim it supported re-evidenced from two other sources. It was not retracted when the document was drafted. Nothing in a document tells you this has happened; only opening the reference does.

The literature search was re-run to the delivery date. Four relevant papers had been published since the original search; all four were appraised and two were added, with the appraisal recorded in the evidence matrix.

4What is handed over

  • Clean copies of all four documents, with the minor findings corrected.
  • Tracked copies, so that nothing was changed silently.
  • The findings log: every finding with its severity, its location, what was done and by whom.
  • The escalation memo covering the three items that are regulatory decisions, each with the options and what follows from them.
  • The claim traceability matrix: all 34 claims mapped to their evidence and to every document that repeats them.
  • The reference verification log: all 84, with the six discrepancies and their resolution.
  • The re-run search strategy, its date, and the appraisal of what it found.
  • The originality report, with matched passages annotated.

Pubrica writes and checks the documents; the claims, the intended purpose and the sign-off remain yours, and your qualified person or regulatory lead owns the strategy. Where a choice is regulatory rather than editorial we bring it to you with the options rather than deciding it. Any AI assistance in drafting is declared.

Prepared by Pubrica. Pubrica is a trading name of Guires®, registered in England, Wales and India.

Download this as a PDF
Before and after · one sentence from a clinical evaluation report, redactedClass IIb device · MDR Annex XIV

As it arrived

The device has been shown to significantly improve healing rates in patients with chronic wounds.

  • Claims a performance the instructions for use do not carry, which is among the most common major non-conformities a notified body raises.
  • “Patients with chronic wounds” is broader than the intended purpose the device is certified for.
  • “Significantly” with no estimate, no interval and no comparator.
  • No source. In a clinical evaluation every performance claim has to be traceable to an appraised study.

As it went out

In the intended population defined in section 1.2 — adults with venous leg ulcers of more than six weeks’ duration — complete healing at 12 weeks was 46% with the device against 33% with standard compression alone (risk difference 13 percentage points, 95% CI 4 to 22; two randomised trials, n = 412, appraised in Annex 4). No claim is made outside that population or beyond 12 weeks.

  • The claim is scoped to the intended purpose as the IFU defines it, word for word.
  • The effect is quantified with its interval, and the comparator is named.
  • The evidence is cited to the appraisal, so an assessor can follow it.
  • The limits of the claim are stated explicitly, which is what stops it drifting into the marketing copy.

Both sentences are true, but only the second meets regulatory requirements. The first version would be returned in a deficiency letter rather than as a comment, which costs a full review cycle.

Benefits

Benefits of Professional Medical Writing

Documents prepared by experienced medical and regulatory writers who work to the applicable guidance.

01Correct register from the first draftA clinical study report that cross-references instead of concluding, a clinical overview that argues instead of restating, and instructions for use that instruct instead of describing. An incorrect register costs a review cycle, which at a notified body or journal takes months rather than days.
02Consistent document setsThe intended purpose identical across the clinical evaluation, the instructions for use and the labelling; the same number rounded the same way everywhere; every residual risk carried through. Inconsistency between documents is the first thing a reviewer finds and the hardest thing to see from inside any one of them.
03Claims supported by evidenceEvery performance and safety claim traced to the evidence, with the conditions attached to the numbers rather than added underneath. Under MDR Article 7 a misleading claim is a regulatory matter rather than a marketing one, and in a manuscript it is the sentence a reviewer builds their report around.
04More time for your clinical specialistsThe people qualified to write a clinical evaluation report are usually the people running the clinical programme, and a 140-page document takes them away from it for weeks. Writing can be delegated to a qualified medical writer, while scientific judgement and sign-off remain with you.

Packages

Medical Writing Service Packages

Each package is run by a writer qualified in your therapeutic area, with an independent reviewer and a project associate who owns the deadline. Single documents are quoted on their own and do not need a package.

Productised

CER and CEP template pack

£700one-off, yours to keep

Sent within 1 business day

A clinical evaluation report and clinical evaluation plan template structured to MDR Annex XIV Part A and MEDDEV 2.7/1 rev 4, with the appraisal method, the state-of-the-art section and the residual-risk mapping already laid out. For teams writing it themselves who want the structure right from the start.

Free

MDR gap analysis

Freeno email required

Returns a scorecard immediately

Your technical documentation checked against MDR requirements section by section — general obligations, GSPR conformity, clinical evaluation, risk management, PMS and PMCF, Annex II — with a scorecard naming where the gaps are rather than a score out of ten.

Single service

Pre-submission review

Quotedon the document set

Report in 7 business days

Your clinical evaluation reviewed as a notified body would review it, with findings classified as critical, major or minor and mapped to the requirement each one breaches. The aim is to avoid an additional review cycle.

The gap analysis is free and does not require an email address. If it shows that your documentation is in good order, you can rely on that result without contacting us.

Our medical writing team5 named, in house

Dr. Daniel Thompson

Head – Medical Writing Services

Leads the writing workstream across regulatory, publications and communications, and oversees the independent check of every document set.

Prof. Rajiv Srinivasan

Principal Scientific Writer – Clinical Research

Clinical study reports to ICH E3, CTD summaries, and the Module 2.5 clinical overview written as an argument rather than a summary.

Dr. Prabha

Medical Communications Lead

Healthcare professional material, plain-language summaries and response documents, written to the code that governs the market they reach.

Mrs. Kavya Reddy

Scientific Publications Specialist

Manuscripts to CONSORT 2025, STROBE, STARD 2015 and PRISMA 2020, with authorship settled against the four ICMJE criteria at the start.

Mr. Lawrence

Clinical Documentation Manager

Protocols, investigator’s brochures and device clinical evaluation to MDR Annex XIV, with every standard cited at its current version.

We name our experts so that their credentials can be checked. Every document set is reviewed by someone who did not write it. We publish names rather than stock photographs, and degrees, registrations and publication records for each person are available on request.

Academic

Author package

Researchers preparing a manuscript for journal submission

From $130development from a complete draft, to 3,000 words

Delivery 10–15 working days

  • ✓Manuscript written from your data, or developed from a draft
  • ✓Written to the reporting guideline your study type requires
  • ✓Journal selection, with the shortlist reasoned
  • ✓Formatting to the journal and the citation style it uses
  • ✓Originality check and correction, and a cover letter

Add later: graphical abstract; response to reviewers; statistical support.

View a sample Select Academic
Regulatory

Device compliance suite

Companies preparing an EU MDR, FDA, SFDA or other device submission

From $2,400one device, one class · CER and CEP

Delivery By submission date

  • ✓Clinical evaluation report to Annex XIV and MEDDEV 2.7/1 rev 4
  • ✓Literature search, appraisal method and evidence matrix
  • ✓Instructions for use to ISO 20417, and labelling content
  • ✓Risk-benefit determination, tied to the risk file
  • ✓PMS and PMCF plan, each objective with a threshold
  • ✓Cross-document consistency check, with the QC report

Add later: PMCF report; usability write-up; eIFU adaptation.

View a sample Select Regulatory
Clinical

Trial documentation

Sponsors and CROs running a study, from protocol through to submission

From $3,200one study · protocol or clinical study report

Delivery By milestone

  • ✓Protocol to SPIRIT, with amendments as they arise
  • ✓Investigator brochure and informed consent documents
  • ✓Clinical study report to ICH E3, with narratives
  • ✓CTD summaries and the Module 2.5 clinical overview
  • ✓Plain-language summary for participants and the registry

Add later: PSUR and DSUR; risk management plan; the manuscript.

View a sample Select Clinical
Commercial

Launch and digital health content

Biotech, MedTech and digital health teams raising funds, partnering or launching

From $780one asset set · claims checked against the labelling

Delivery By project scope

  • ✓Scientific white paper and executive summary
  • ✓Mechanism-of-action or algorithm narrative
  • ✓Scientific slide deck for investors or clinical audiences
  • ✓Product and company web content, claims checked
  • ✓Competitive landscape summary

SaMD performance reports and validation summaries sit here.

View a sample Select Commercial

A cross-document consistency check can also be commissioned on its own for a document set written by another team. Four documents are read against each other, with every claim traced and every number compared. Clients most often commission it a few weeks before submission, when the documents are final and there is still time to act on the findings.

Quality Assurance

Our Service Commitments and Limitations

A document can be of high quality and still be rejected, because the decision rests with an editor, assessor or reviewer. Our terms are set out below before you commit to a project.

The Pubrica guarantee

Revision Support Until Agreed Requirements Are Met

We revise the document until it meets the brief and the standard it is written to, with no limit on rounds within the agreed scope. We offer revision rather than refunds, because a refund does not deliver a submission-ready document.

01

Unlimited revisions within the agreed scope

Within the agreed scope, with no limit on rounds or time. If guidance is revised, a reviewer requests something new or a stakeholder joins late, we revise the document.

02

Corrections at our cost

If a guideline is misapplied, a reference is wrong or a number is inconsistent between documents because of our error, we correct it free of charge and tell you first.

03

Delivered on the date agreed

Submission windows and journal deadlines are fixed. If a date is at risk, we tell you early and explain the options.

04

Final decisions remain with you

Where a choice is regulatory or scientific rather than editorial, it comes to you with the options and their consequences. We do not decide what your product claims.

05

Mutual NDA on request

Signed in both directions before you send any material, at no cost. Your question, your data and our working relationship remain confidential, and we are happy to sign your NDA rather than requiring ours.

9.4/10

Average client rating

From 3,000 responses to Pubrica’s own post-delivery survey, sent to every client at handover, January 2024 to June 2026. The figure comes from our own records.

Service limitations. We cannot guarantee publication, approval or a notified body review without findings, because those decisions rest with editors, assessors and reviewers. We do not write claims the evidence does not support, and where a document depends on such a claim we will tell you. We do not create or adjust data, remove unfavourable findings, or describe a study as having met an endpoint it did not meet. We are not your regulatory consultant of record: we write the documents and report what we find, and your qualified person or regulatory lead owns the strategy and sign-off.

Subject-specialist writers

Writers hold a master’s degree or a doctorate in life sciences, medicine or pharmacy and have at least five years in the field, and they are assigned by therapeutic area rather than by who is free. Where a project sits between two areas, two people are assigned. Recruitment spans the United Kingdom, Europe, India and Asia-Pacific, and nothing is subcontracted outside the vetted network.

Reference verification against the source

References are checked against the source rather than against the citation, and the results are reported as numbers, including any references found to be incorrect. This check also identifies papers retracted since the document was first drafted.

NDA, GDPR and data privacy

A non-disclosure agreement is signed before any material moves, and writers and project staff are additionally bound by internal confidentiality agreements. Pubrica works with researchers and companies in India, across the United Kingdom and Europe, in North America, throughout Asia-Pacific and the Middle East, and in Africa and Latin America, and every project is handled the same way. Unpublished data, technical files and pre-submission dossiers are held under GDPR, kept only as long as the project needs them, never used to train anything, and never shared outside your project team.

Disclosed medical writing support

Professional medical writing is permitted by the ICMJE and required to be disclosed. Where a writer contributes substantially to a manuscript they are named in the acknowledgements with the funding source stated, and where a contribution meets the authorship criteria we say so and let you decide. This is disclosed professional writing, not ghostwriting. Any use of AI in drafting is declared to you, and we follow whatever your journal or authority requires about it.

Client Stories

Client Feedback on Medical Writing Projects

Rephrased from client feedback.

“They turned our raw data into a manuscript that was ready to submit, and the part we had underestimated was how much of the work is deciding what the paper is actually claiming.”
Dr. Siddharath — Academic researcher · India Published inPLOS One3
“We needed the study report and the CTD summaries under real time pressure. What made it work was that the two documents were written to agree with each other from the start.”
James Mitchell — Regulatory affairs manager · United States SubmissionTo be added—
“The consistency check found a claim in our clinical evaluation that our instructions for use did not support. We would not have caught it, and our notified body would have.”
Dr Anna Müller — Regulatory lead · European Union SubmissionTo be added—

FAQs

Medical Writing FAQs

If you are unsure which documents your project requires or which standard applies, please ask an expert. No quote is required.

We offer six service areas, and each can be commissioned separately. Scientific and academic writing: manuscripts, narrative and systematic reviews, meta-analyses, case reports and thesis chapters. Regulatory medical writing: protocols, investigator brochures, informed consent documents, clinical study reports to ICH E3, CTD summaries and the Module 2.5 clinical overview, patient narratives and safety reports. Medical device and digital health writing: clinical evaluation reports, investigation reports to ISO 14155, instructions for use, labelling, surveillance and PMCF documents, and SaMD performance and validation reports. Pharmaceutical and biotech content: white papers, monographs, target product profiles, mechanism-of-action narratives and field medical decks. Patient and healthcare professional communication: plain-language summaries, information leaflets, brochures and digital content. Medical editing and quality support: substantive editing, reference verification, consistency checking across a document set, originality checking and formatting. Visual abstracts, animation scripts and data presentation for algorithm validation are quoted alongside a writing project.

The document itself, formatted to the journal, template or submission structure it is going to, and with every number traced to its source and every claim to the evidence behind it. Alongside it, an annotated outline agreed before drafting so you saw the structure before the prose existed; a reference list verified against the sources rather than matched against the citations, with any discrepancies reported; an originality report; and, where you want one, the quality control report showing what was checked, what was found and what was done about it. Where the document belongs to a set, you also get the consistency check across that set. We do not make regulatory or scientific decisions for you; where one is needed, we present the options and their consequences.

We ask for seven items, listed roughly in order of usefulness. The field and the product or study it concerns. The region, because a submission to the FDA, the EMA, the MHRA, the TGA, the SFDA or CDSCO is a different document. The reader — a named journal, an authority, a notified body, clinicians, patients. The purpose: what this document has to achieve and what happens if it does not. The material itself: data, protocol, draft, risk file, previous dossier or technical file. Any guidelines that bind you, whether a journal’s, a sponsor’s template or your institution’s. And any references you want used or would like considered. Two further items are especially useful and are often omitted: the previous version of the document, and whatever a reviewer, assessor or notified body said about it last time.

A master’s degree or a doctorate in life sciences, medicine or pharmacy, and at least five years of professional experience in the field they write in. Writers are assigned by therapeutic area rather than by who is available, because subject depth is what makes a document credible to specialist reviewers. Regulatory writers additionally work to the specific guidance their documents are governed by, such as ICH E3 and E6 for clinical study reports, MDR Annex XIV and MEDDEV 2.7/1 rev 4 for clinical evaluation, and ISO 14155 and ISO 20417 for device work. That guidance changes, and our writers keep current with each revision. Recruitment spans the United Kingdom, Europe, India and Asia-Pacific. Where a project sits between two therapeutic areas, two writers are assigned.

A project associate reads the brief and comes back with the questions it raises, usually the same day. A non-disclosure agreement is in place before any material moves. A subject-matter expert is then assigned by therapeutic area, and the first deliverable is not prose but an annotated outline: every section, what goes in it, and which source it comes from. You sign that off before drafting starts, because restructuring a finished 140-page document takes far longer and affects every cross-reference. Drafting follows, then independent review, quality control, reference verification and an originality check, each signed off separately. The document is delivered with its reports, version-controlled throughout, and revised within the agreed scope until it is right.

Four things we will hold to: delivery on the date agreed, with early warning if a date is genuinely at risk; a writer qualified in your therapeutic area; original work, checked and reported rather than asserted; and a document written to the standard that governs it and consistent with the rest of its set. If any of those is not met, we revise or rework it at our cost, with no cap on rounds inside the scope agreed. Refunds are considered only where a specific agreed guarantee has failed within the agreed scope, because a refund leaves you with the same deadline and no document. What we cannot guarantee is the decision: publication, approval, or a review without questions belongs to an editor, an assessor or a notified body reviewer.

Writing is done by in-house writers and by a vetted extended network, all of whom are under the same confidentiality agreements and the same quality process, and nothing is subcontracted outside that network. The review and quality control is always internal and always done by a second writer who did not write the document, because a writer checking their own work reliably re-reads what they meant rather than what is on the page. Where a project needs a specialist we do not have — a particular device class, a rare disease, a regulatory route we have not run recently — we say so and either bring in someone named and vetted for it, with your agreement, or decline the work. We do not assign writers who would be learning the subject area on your project.

Yes. Each document is written to the specific ICH guideline that governs it. Clinical study reports are written to ICH E3, which decides what appears in which section and where the narratives and listings are cross-referenced from. The studies those reports describe are conducted under ICH E6, now in its R3 revision, which moves the framework towards a risk-proportionate approach and changes what a protocol and a monitoring plan are expected to contain. Statistical principles follow ICH E9, including the addendum on estimands, which is why a modern protocol has to state the estimand rather than merely the analysis population. Informed consent documents, investigator brochures and safety reporting all sit inside the same framework. Which version applies is decided by your submission rather than by what was current when we last wrote this kind of document, and we check that at scoping.

Yes. Clinical evaluation reports are written to Annex XIV Part A of the EU MDR, using the appraisal method in MEDDEV 2.7/1 rev 4 and the MDCG guidance that has grown up around it, including MDCG 2020-7 for the post-market clinical follow-up plan. Beyond the template, three requirements determine the quality of the report: the state of the art has to be established and quantified rather than asserted, so a reviewer can see what the device is being compared against; every source has to be appraised rather than listed, with its weight and its limitations stated; and every residual risk arising from the clinical data has to be carried explicitly into the risk file and into the instructions for use. That last one is where most non-conformities come from — a clinical evaluation claiming a performance the labelling does not support, or the reverse — and it is why we check a clinical evaluation, an instructions for use and the labelling against each other rather than one at a time.

Yes, on every project and before any material moves — yours if you have one, ours if you would rather. Writers and project staff are additionally bound by internal confidentiality agreements. In addition, material is held on access-controlled systems under a quality management system certified to ISO 9001:2015, kept only as long as the project needs it and then deleted on your instruction, never used to train any model, and never shared outside your project team. Unpublished data, technical files and pre-submission dossiers are among the most sensitive documents an organisation owns, and they are treated that way whether the project comes from India, the United Kingdom, Europe, North America, Asia-Pacific, the Middle East, Africa or Latin America. We also decline work where we are already writing for a direct competitor on the same submission, and we tell you that is the reason.

The answer depends on the device class. MDR Article 61(11) requires the clinical evaluation to be updated throughout the life cycle with data from the PMCF plan; the annual obligation in that article attaches specifically to the PMCF evaluation report and, where indicated, the summary of safety and clinical performance. In practice notified bodies expect an annual refresh of the CER itself for class III and implantable devices, and it is worth knowing that this is an expectation rather than the wording of the Regulation. For other classes the Regulation sets no interval at all; the familiar two-to-five-year figure is MEDDEV 2.7/1 rev 4 guidance, which is MDD-era. The CER scoping tool above works this out for your device class.

Yes. They are different documents, not reformatted versions of the same one. The MDR clinical evaluation is a benefit-risk argument built on appraised clinical data against the intended purpose in the instructions for use, assessed by a notified body. An FDA 510(k) is a substantial equivalence argument against a predicate device; a De Novo or a PMA is different again. What travels between them is the underlying evidence and the analysis; what does not is the structure, the standard of proof and the reader. We write each to its own framework and tell you where a claim supportable in one jurisdiction is not supportable in the other.

A writer produces the document from your data, your protocol and your decisions; an editor improves a document that already exists. The distinction affects cost: writing costs more than editing, but no amount of editing turns a clinical study report missing its cross-references into a compliant one. The practical test is whether the structure is right. If the document says the right things in the wrong order with the wrong emphasis, that is writing. If it says the right things and reads badly, that is editing. We will tell you which you need, including when editing is sufficient.

Yes, and it is a large part of what we do. The extension under Regulation (EU) 2023/607 runs to 31 December 2027 for class III and class IIb implantable devices and to 31 December 2028 for other class IIb, class IIa and class I devices requiring notified body involvement. The extension is conditional, and the conditions had dates in 2024 that have now passed. What the clinical evaluation has to demonstrate is sufficient clinical evidence in the sense of MDCG 2020-6, which sets a hierarchy from clinical investigations down through registries and equivalence to bench testing. Most legacy CERs fail on that hierarchy rather than on the writing.

We use AI tools for search, structure and consistency checking across long documents, and not to generate substantive scientific content that then goes out under your name unverified. Every factual claim in a document we deliver is traceable to a source in your material or in the literature, and that is checked by a person. Declaration follows the destination: ICMJE added a section on artificial intelligence in publishing in its January 2026 update, journals expect a statement of what was used and where, and regulatory submissions have their own expectations. We will tell you what has to be declared and draft the wording.

Request a Free Document Review by a Medical Writer

We confirm which documents the work requires, which standard governs each one, which must be consistent with each other, and what is missing. The review takes two business days, at no cost and with no obligation.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.